HemaTopics are HemaSphere pubs focusing on hot heme topics. Today we focus on the latest HemaTopic by Sci Ed F Vinchi discussing advances in gene therapies for pts w/ hematologic diseases, such as β-Thalassemia, sickle cell disease & hemoglobinopathies.👉
Infection has emerged as a chief cause of NRM post CAR-T therapy. In this study authors explore severe & life-threatening inf. post licensed CAR-T therapy in large B-cell lymphoma. Authors examine pts who experienced ≥2 infections & those at ⬆️ risk👉
In this first ever report on hereditary spherocytosis (HS) mutational spectrum in Central Europe, authors analyzed 69 pts w HS in Austria. The findings emphasize combining family, lab, clinical, & NGS analyses for accurate HS patient characterization👉
🎉Our first 2024 issue is finally online, with more papers coming next week!
We're proud to now publish with Wiley, offering easy submission, transformative agreements (many authors will incur zero APCs!), + much more. Lots of good changes, all while we
✏️What skills are most important when serving as a manuscript peer reviewer? Our editors weigh in 👉 .
This is the final topic of the 2nd season of HemaSphere’s ‘Meet the Editors’ series, offering short, casual anecdotes from our experts. We hope you have
💡HemaSphere's June issue is open & hosts excellent content to read and share. As well, more publications will be added ahead ongoing. Have a browse through what's new 👉.
#hematology
#HemeTwitter
#MedTwitter
🏆 Each month HemaSphere Chief Editor Prof Jan Cools selects Editor Highlights, which he calls out as new, must-read papers. We invite you to read, download, share, and cite this month’s Editor’s Highlight pick 👉
💡How can we generate high-quality PRO data in MDS trials & better inform decision making and care of patients with
#MDS
? Authors delve into challenges of trial design, strategies for assessment, statistical approaches for time-to-event analyses, & more 👉
🎉Exciting news: our 2023 impact factor is 12.1! We are thankful for our editors, authors, reviewers, & readership. While this is 1 journal metric of many, it's an important milestone. We remain committed to high quality science + service. Browse our
#OpenAccess
content:
💡HemaSphere's August issue is open and already offers exciting content. Additional publications are forthcoming. Have a browse through what's new so far👉.
#hematology
#HemeTwitter
#OpenAccess
🏆Editor Pick: Our Editor in Chief, Prof Jan Cools, calls out new, must-read papers monthly. Read, share, & cite this month’s pick: The MLL–Menin Interaction Is a Therapeutic Vulnerability in NUP98-rearranged AML, by M Rasouli et al 👉
#HemaSphereHighlights
The hematology community has lost a leading scientist who made important contributions to leukemia research, and who we all loved as a wonderful collaborator and friend. Thank you, Pieter Van Vlierberghe, for your support to EHA and HemaSphere.
🏆HemaSphere Chief Ed Prof Jan Cools selects Editor Highlights, calling out new, must-read papers. March 📰 Concomitant inhibition of the thioredoxin system & nonhomologous DNA repair potently sensitizes Ph+ lymphoid leukemia to tyrosine kinase inhibitors👉
The 2021 impact factors are now final (June was a prelim release) so we had a cozy (🇳🇱gezellig) celebration with our colleagues. A warm thank you to
#EHA
for its support over the years 😍. Now back to publishing - Oct issue out soon.
#teamwork
#thanks
#ImpactFactor
#HemeTwitter
🤔If you could choose to witness any scientific breakthrough, what would it be? See what some of our editors say 👉
This is topic 2 of the 2nd season of HemaSphere’s ‘Meet the Editors’ series, offering short, casual anecdotes from our experts. Get to know
Breaking news from our Chief Editor: HemaSphere has earned an
#ImpactFactor
of 8.3 !
We are *delighted*. Deepest thanks to
@EHA_Hematology
and to HemaSphere's editors, authors, reviewers, & readership.
🔀Have you ever received a piece of advice that has remained applicable no matter how life has twisted + turned? Hear our editors reflect upon the most lasting advice received during their aspiring scientist + researcher years 👉
This is topic 4 of the 2nd
💡What are the most exciting research topics our journal editors have come across recently? Have a look/listen👉
This is topic 1 of the 2nd season of HemaSphere’s
#MeetTheEditors
series, offering short, casual anecdotes from our experts. Get to know our
#GeneTherapy
&
#Hemophilia
- what's next so that widespread application of this treatment paradigm can be enabled? Read this recent, comprehensive review: the current state of hemophilia gene therapy and outlook on licensing a gene therapy product
👉
🥁The
#HemaSpherePodcast
is live, with episode 1 on our website + all major podcast platforms (Spotify, Apple Podcast, etc). Listen + enjoy casual, insightful discussions about
#hematology
research. 🎧What to do next for "long COVID-19" of researchers? 👉
HemaTopics are HemaSphere pubs focusing on🔥heme topics. This week we focus on the latest HemaTopic by Sci Editor F Vinchi: Luspatercept: A peaceful revolution in the standard of care for myelodysplastic neoplasms👉
@IronResearchLab
Such a pleasure to meet the winners of the HemaSphere 2024 awards, recognizing the importance of their studies for the heme field & for supporting to HemaSphere. Congrats to Marc Raaijmakers et al for their excellent study on
#azacytidine
treatment for
#VEXAS
syndrome.
📖:
Authors generated a single-cell expression atlas of 119,000
#AML
cells &
#stemcells
in paired dx-relapse samples & ID role of HIF pathway in drug res, demonstrating chem inhibition of HIF cooperates w/ SOC chemo to impair AML growth & elim AML stem cells👉
It is an honor to meet the winners of the HemaSphere 2024 awards, recognizing the importance of their studies for the heme field & for supporting to HemaSphere. Congrats to Mariana Bastos-Oreiro et al for their study on risk factors & mortality of COVID-19 in pts with
#lymphoma
.
Real talk:
#BoneMarrowBiopsies
are not generally well tolerated. They cause
#ProceduralPain
, sometimes severe/persistent, for most ppl. Effective but underutilized interventions to⬇️pain exist, but how can we train practitioners about them? Read more 👉
Congratulations to David Kent, 2022 Janet Rowley Award recipient at
#ISEH2022
(& one of our amazing Scientific Eds!). A well-deserved recognition for his fantastic research accomplishments as well as his passion for advancing the work-life balance and recognition of scientists.
❓What helps you enjoy your commitments? Hear from some of our editors as to what is rewarding about being involved with HemaSphere 👉
This is topic 3 of the 2nd season of our ‘Meet the Editors’ series. Get to know our team + hear their insights about
🏆 Editor highlight: Effects of fedratinib on patient-reported MF-related symptoms + HRQoL (Phase III
#JAKARTA
) for pts with no previous ruxolitinib. Explore the positive results & insightful discussion 👉
@mpdrc
@harrisoncn1
#HemaSphereHighlights
#mpnsm
News: HemaSphere's 2023 impact factor is 12.1. We are proud of and thankful for our editors, authors, reviewers, and readership!! 🎉
@EHA_Hematology
@WileyOnc_Hem
Happy to share that the 2023 journal impact factor of
@Hemasphere_EHA
is 12.1 !!!!! Although this is only one of the journal metrics, it is an important independent quality mark (Source: Clarivate, pending update of the JIF calculation).
@EHA_Hematology
#hematology
#OpenAccess
In this paper, authors assess the association between CHIP and COVID-19 severity in the Danish population using univariable and multivariable logistic regressions👉
Final chapter now online 🙌! Mapping urgent priorities in research & clinical science via the
#EHA
#ResearchRoadmap
: Malignant Lymphoid Diseases. Guiding the way to a more focused, funded European heme research future 👉
#MalignantLymphoma
#lymsm
Along with our high-quality publications, a lot of good things are happening at HemaSphere. We're immensely proud to confirm that HemaSphere's 2022 impact factor is 9.1 🎉. In addition, we're looking forward to the
#EHAReCon2024
program (abstract submissions due Friday!). Plus,
🎧The newest
#HemaSpherePodcast
episode is here! How can
#MachineLearning
be used for advanced heme-on disease prognostication + beyond? Authors of a recent HemaSphere publication discuss challenges + outcomes in utilizing a novel
#myelofibrosis
survival model that aids in risk
Final analysis of the Phase III GALLIUM trial demonstrates long-term benefits of obinutuzumab-based immunochemotherapy, confirming its role as a standard of care for 1st-line treatment of pts with follicular lymphoma. 👉
#lymphoma
The Abstract Book for the
#EHA25Virtual
Congress contains exciting and ground-breaking research in all areas of
#hematology
. It is an official
#HemaSphere
supplement and available online ➡️
👏Congratulations to all of the authors & contributors!
Greetings from the EHA Research Conference in Bulgaria ⛄️ where the group is discussing molecular vulnerabilities in
#metabolism
& heme disorders. It's a closed meeting so we can't post content, but we look forward to meeting those of you here on the mountain. To those at home,
🎉The
#HemaSphere
June issue is now online 🎉
Browse our exciting new hematology publications linked to the
#EHA2021
scientific program 👉
As a reminder, our content is always
#OpenAccess
. Feel free to share widely.
Are you looking for novel, high-quality publications about basic, translational, & clinical
#hematology
?
#HemaSphere
,
#EHA
's peer-reviewed journal (2021 IF 8.3) can help. Browse our 6+ yrs (more to come!) of excellent content, all open access 👉 🩸🧬🔬
We are proud of our HemaSphere 2024 award winners who authored key studies for the heme field & who supported HemaSphere. Congrats to Heike Pahl, Jonas Jutzi, et al for their excellent study on LSD1 Inhibition
#MPN
mouse models 📖: .
@CoolsJn
"The danger for ill people is that they are taught how to be ill by professionals" (Arthur Frank). Patients + clinicians make sense of illness through stories. How can we frame these stories & illuminate our interactions? 👉
#HemaTopics
#MedicalHumanities
It is an honor to meet the winners of the HemaSphere 2024 awards, recognizing the importance of their studies for the heme field & for supporting to HemaSphere. Congrats to Hélène Lapillonne et al for their study on molecular profiling in childhood
#AML
. Coauthor C Preudhomme
June brings new impact factors, journal rankings, and also lots of additional exciting developments! Here are 3 things we're excited about right now. Read our
#OpenAccess
content at .
🏆Editor Pick: Can we predict individual effects of switching from standard to extended half-life products in people with
#hemophilia
? Explore study results + access predictive tables 👉
#HemaSphereHighlights
#pharmakokinetics
🌴Summer reading list: have you noticed our tweets starting with '🏆 Editor's Pick'? Our Editor in Chief highlights exciting, key articles monthly. We compiled all Editor highlights for the first half of 2023 - have a look:
Q1:
Q2:
For those of you at
#EHAReCon22
, the poster session yesterday was 🔥! To allow for more space & less voice strain, today we've moved half of the posters outside (other half = same place as yesterday).
#ScienceWithAView
#KeepUpTheGreatTalks
Let's celebrate HemaSphere co-editor in chief, Andreas Engert, as he rotates off from his leadership role at HemaSphere today. What a journey it has been! We wish him all the best ahead, & we would like to share some of his accomplishments at the journal to date. Herewith, a 🧵:
Authors show correlation between mechanical properties of B lymph cells & actomyosin cortex organization. Ibrutinib restores the physiological mechanical properties of CLL cells until onset of resistance. 👉
📢Exciting news:
#HemaSphere
will receive an impact factor in June 2022! This is an important milestone, and we're so thankful🤝to all of you - our authors, reviewers, editorial board, ambassadors, & readership. Cheers to the positive ☀️road ahead.
@EHA_Hematology
#OpenAccess
Syed Milan takes the floor to address audience questions after his excellent
#EHAReCon22
presentation on dysregulated ligand receptors in myelodysplasia.
#MDSsm
#MesenchymalStemCells
🏆Editor Pick: "A better understanding of the molecular mechanisms behind in vivo
#HSC
fate/identity acquisition within the dynamic cell hierarchies in the embryo is [sic] of vital importance..." 👉
@DrChrisSVink
@EdinUni_MeetCIR
#HemaSphereHighlights
💡Dawn Swan et al review
#cyclophosphamide
treatment for
#MultipleMyeloma
: its effect on the immune system & how it can be used synergistically with other treatment modalities such as
#IMiDs
,
#mAbs
, and cellular therapies. Read the full article 👉
🏆Editor Pick: Authors analyzed CNAs (
#CopyNumberAlterations
) in 493 pediatric pts with B-ALL being treated under the ICiCLe protocol. Read why they advocate for routine CNA testing + screening, and CNA risk status in future trials 👉
#HemaSphereHighlights
Want to expand your knowledge on basic & translational research in
#hematology
? Register now for the 4th
#YoungEHA
Research Meeting (accessible free of charge, outside of the
#EHA25Virtual
Congress Platform). It's happening Jun 11 (Thurs), from 9.30am.
👉